榴莲视频

Androgen-deprivation therapy (ADT) entails lowering serum testosterone levels to castrate levels and forms a cornerstone of the management of hormone-sensitive advanced prostate cancer; however, the benefit of ADT is partially offset by its detrimental metabolic and cardiovascular adverse effects. ADT decreases insulin sensitivity while promoting dyslipidemia and sarcopenic obesity, which leads to an increased risk of cardiovascular morbidity and potentially mortality.

The risk seems to be highest in elderly patients who have had recent cardiovascular events before starting ADT. It is prudent to engage in an individualized risk–benefit discussion and develop a cohesive multidisciplinary management plan to medically optimize and closely observe these patients before and during treatment with ADT.

Cardiovascular risk should be discussed and balanced against the benefits for cancer outcomes, and all efforts should be made to optimize the patient before and during therapy to mitigate deleterious effects. A collaborative multidisciplinary approach is key to successfully managing the oncologic and cardiac comorbidities of this unique cohort of patients.

Comment